The Food and Drug Administration on Friday approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar control in adults with diabetes mellitus. Both Tresiba and Ryzodeg are manufactured by Novo Nordisk.
Teva Pharmaceutical on Friday announced that it entered into a definitive agreement to acquire Gecko Health Innovations, which focuses on developing software and product solutions to aid in compliance and adherence improvement in the management of respiratory diseases.
Health benefit plan cost trend rates for 2016 will increase for most medical plan options and increase substantially for prescription drug coverage to double-digit rates, according to forecasts compiled in the 2016 Segal Health Plan Cost Trend Survey, Segal’s nineteenth annual survey of health plan cost trends. Trend is the forecast of annual gross per capita claims cost increases.
The Wall Street Journal is examining the potential that biosimilars can have in the market for biotechnology drugs by looking at how they have been received in Europe to highlight their potential in the U.S. following the launch of Zarxio, the first U.S. biosimilar, earlier this month.